BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cells » MSCs » Page 3

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update

July 23, 2020 By Cade Hildreth (CEO)

Cynata COVID-19 trial

MELBOURNE, Australia, May 08, 2020 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated guidance on its wider clinical development pipeline. [Read more…]

Filed Under: Coronavirus (COVID-19), iPS Cells, MSCs, Stem Cell News Tagged With: cynata therapeutics

Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)

July 23, 2020 By Cade Hildreth (CEO)

Vitro Biopharma COVID-19

GOLDEN, CO  July 14, 2020 — Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®. [Read more…]

Filed Under: Cell Therapy, Coronavirus (COVID-19), MSCs, Press Releases, Stem Cells Tagged With: COVID-19, GIOSTAR

Citius to Pursue IND for Use of Its Induced MSCs in COVID-19 Induced ARDS

July 1, 2020 By Cade Hildreth (CEO)

Citius iMSCs COVID-19
  • Citius receives FDA Response on Pre-IND application for its induced mesenchymal stem cells (iMSCs) to treat ARDS induced by COVID-19

  • FDA provides specific guidelines to study iPSC-derived MSCs, preparing Citius to submit an IND application for its iMSC therapy

  • The Citius iMSC is an allogeneic MSC product manufactured by expanding material from a master cell bank

[Read more…]

Filed Under: Coronavirus (COVID-19), iPS Cells, MSCs, Press Releases, Stem Cell News, Stem Cells Tagged With: COVID-19

Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using MSCs a Prophylactic Against COVID-19

June 26, 2020 By Cade Hildreth (CEO)

Celltex COVID-19

June 26, 2020, HOUSTON — Celltex, a Houston, Texas-based biotechnology company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application (IND 22055) to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus Disease 2019 (COVID-19). [Read more…]

Filed Under: Adipose SCs, Cell Therapy, Coronavirus (COVID-19), MSCs, Press Releases, Stem Cell News, Stem Cells

American Academy of Stem Cell Physicians To Host 1st Virtual Congress & Safety Panel (August 1-2, 2020)

June 11, 2020 By Cade Hildreth (CEO)

AASCP Virtual Congress

While COVID-19 has caused many events to be rescheduled, a highly anticipated and sought after American Academy of Stem Cell Physicians (AASCP) meeting is back by popular demand. Over August 1-2, 2020, the AASCP will host its first virtual congress, allowing for wide-scale participation at an unprecedented scale. The Academy is expecting 5,000 attendees, as the program will be broadcasting internationally.
[Read more…]

Filed Under: Adipose SCs, Cell Therapy, MSCs, Stem Cell News, Stem Cells

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 57
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297

Featured Posts

Stem cell conferences

The Complete Guide To Virtual Stem Cell Conferences in 2021

CO.DON AG

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

Safety Chart | The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.